India's biotechs rely on innovative plans to fund growth

Despite some serious limitations on financing, India's biotech sector has been going gangbusters, according to a new report from the Association of Biotechnology Led Enterprises in Bangalore. The association says the Indian biotech sector is expanding at a rate of 37.5 percent, double the global rate of expansion. The industry is expected to hit $5 billion in revenue annually by 2010. One of the biggest obstacles to even faster growth, say analysts, is that venture capitalists in the country have been reluctant partners. As a result, Indian biotech companies have been turning to a number of innovative strategies to help fuel their growth. One of those strategies is setting up a U.S. research and development subsidiary. Others look to gin revenue quickly or are turning to global banks for funds. But the report notes that a new business model is still needed that will help fuel expansion.

- read the Red Herring report on the Indian biotech sector

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.